Safinamide Mesylate is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 2015 and is indicated in parkinson disease. It is grouped under the following drug class(es): Dopamine agents and Neurotransmitter agents. Its therapeutic use is listed as central nervous system (CNS) agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Propanamide, safinamide methanesulfonate and Safinamide mesylate [USAN]. Its PubChem CID is 3038502.
Safinamide mesylate
| CAS No | 202825-46-5 |
|---|---|
| Molecular Formula | C18H23FN2O5S |
| Molecular Weight | 398.5 g/mol |
| Synonyms | (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide;methanesulfonic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Safinamide Mesylate is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 2015 and is indicated in parkinson disease. It is grouped under the following drug class(es): Dopamine agents and Neurotransmitter agents.
The listed CAS number is 202825-46-5.
The listed molecular formula is C18H23FN2O5S.
The listed molecular weight is 398.5 g/mol.
(2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide;methanesulfonic acid.
The source lists Propanamide, safinamide methanesulfonate and Safinamide mesylate [USAN].